These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 17605893

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland.
    Girvin B, Rafferty T, Stevenson MR, Johnston GD.
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):153-7. PubMed ID: 15072114
    [Abstract] [Full Text] [Related]

  • 9. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 10. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E, Toubouti Y, Hunsche E.
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [Abstract] [Full Text] [Related]

  • 11. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
    Barozzi N, Tett SE.
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A.
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
    Schneeweiss S, Glynn RJ, Avorn J, Solomon DH.
    J Clin Epidemiol; 2005 Jan; 58(1):98-102. PubMed ID: 15649677
    [Abstract] [Full Text] [Related]

  • 16. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals.
    Schüssel K, Schulz M.
    Pharmazie; 2006 Oct; 61(10):878-86. PubMed ID: 17069430
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.